JP2002502836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002502836A5 JP2002502836A5 JP2000530488A JP2000530488A JP2002502836A5 JP 2002502836 A5 JP2002502836 A5 JP 2002502836A5 JP 2000530488 A JP2000530488 A JP 2000530488A JP 2000530488 A JP2000530488 A JP 2000530488A JP 2002502836 A5 JP2002502836 A5 JP 2002502836A5
- Authority
- JP
- Japan
- Prior art keywords
- xii
- embedded image
- vii
- prodrug
- hydroxylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 238000007262 aromatic hydroxylation reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- IHAWCLXPXUOJEO-JXMROGBWSA-N COc1ccc(/C=C/C(c(cc2OC)cc(OC)c2OC)=O)cc1 Chemical compound COc1ccc(/C=C/C(c(cc2OC)cc(OC)c2OC)=O)cc1 IHAWCLXPXUOJEO-JXMROGBWSA-N 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9802522.4A GB9802522D0 (en) | 1998-02-06 | 1998-02-06 | Hydroxylation activated prodrugs |
| US9802522.4 | 1998-07-14 | ||
| US09/115,015 | 1998-07-14 | ||
| US09/115,015 US6214886B1 (en) | 1998-02-06 | 1998-07-14 | Hydroxylation activated prodrugs |
| PCT/GB1999/000155 WO1999040056A1 (en) | 1998-02-06 | 1999-02-02 | Hydroxylation activated prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002502836A JP2002502836A (ja) | 2002-01-29 |
| JP2002502836A5 true JP2002502836A5 (https=) | 2006-03-16 |
| JP4642226B2 JP4642226B2 (ja) | 2011-03-02 |
Family
ID=26313066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000530488A Expired - Fee Related JP4642226B2 (ja) | 1998-02-06 | 1999-02-02 | ヒドロキシル化により活性化されたプロドラッグ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6677383B1 (https=) |
| EP (1) | EP1051383B1 (https=) |
| JP (1) | JP4642226B2 (https=) |
| AT (1) | ATE272040T1 (https=) |
| AU (1) | AU2173899A (https=) |
| CA (1) | CA2319836C (https=) |
| DE (1) | DE69918950T2 (https=) |
| ES (1) | ES2226332T3 (https=) |
| WO (1) | WO1999040056A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4642226B2 (ja) | 1998-02-06 | 2011-03-02 | デ モントフォート ユニヴァーシティ | ヒドロキシル化により活性化されたプロドラッグ |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
| US7321050B2 (en) | 1999-12-06 | 2008-01-22 | Welichem Biotech Inc. | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues |
| WO2001042231A2 (en) * | 1999-12-06 | 2001-06-14 | Welichem Biotech Inc. | Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
| GB0007401D0 (en) | 2000-03-27 | 2000-05-17 | Cancer Res Campaign Tech | Substituted chalcones as therapeeutic compounds |
| GB2378948B (en) * | 2000-04-13 | 2004-11-10 | Hsc Res Dev Lp | Novel compounds for modulating cell proliferation |
| ES2299560T3 (es) | 2001-02-22 | 2008-06-01 | University Of Bradford | Derivados de pirrolindol y de pirroloquinolina como profarmacos para el tratamiento de tumores. |
| EP1408960B1 (en) | 2001-02-22 | 2006-05-31 | School Of Pharmacy, University Of London | Benz-indole and benzo-quinoline derivatives as prodrugs for tumour treatment |
| US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| GB0123777D0 (en) * | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
| GB0123780D0 (en) * | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
| EP1438281A4 (en) * | 2001-10-26 | 2006-04-26 | Oxigene Inc | FUNCTIONALIZED STILBENE DERIVATIVES USEFUL AS IMPROVED VASCULAR TARGETING AGENTS |
| GB0126889D0 (en) * | 2001-11-08 | 2002-01-02 | Paterson Inst For Cancer Res | Compounds and their uses |
| DE60313339T2 (de) * | 2002-07-31 | 2008-01-03 | Critical Outcome Technologies, Inc. | Protein tyrosin kinase inhibitoren |
| US7629347B2 (en) * | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| EP1591117A4 (en) * | 2003-02-04 | 2006-04-26 | Yakult Honsha Kk | BCRP (BREAST CANCER RESISTANCE PROTEIN) INHIBITOR |
| EP1727822A4 (en) * | 2004-03-26 | 2007-05-09 | Hsc Res Dev Lp | NEW COMPOUNDS FOR MODULATING CELL PROLIFERATION |
| NZ562143A (en) | 2005-03-30 | 2010-12-24 | Yakult Honsha Kk | Dimethoxyphenyl-acrylonitrile derivatives and uses thereof in the treatment of cancer |
| EP2121681B1 (en) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| US7784455B1 (en) * | 2007-09-18 | 2010-08-31 | Chong Carlton Le Loong | Reusable pellet shooting grenade |
| CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| GB0803071D0 (en) * | 2008-02-20 | 2008-03-26 | Care Technologies Inc | Cancer detection methods and techniques |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176433A (ja) * | 1984-09-21 | 1986-04-18 | Toyobo Co Ltd | 新規なカルコン誘導体 |
| US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
| AU632992B2 (en) * | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
| US5287386A (en) | 1991-03-27 | 1994-02-15 | Thinking Machines Corporation | Differential driver/receiver circuit |
| US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
| DE4236237A1 (de) | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
| DE4309344A1 (de) | 1993-03-23 | 1994-09-29 | Gerhard Prof Dr Eisenbrand | Antineoplastische Mittel mit verstärkter Wirksamkeit |
| US5276058A (en) * | 1993-06-09 | 1994-01-04 | Nippon Hypox Laboratories Incorporated | 3,4-dihydroxychalcone derivatives |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| FR2710798B1 (fr) | 1993-09-27 | 1995-11-10 | Alcatel Mobile Comm France | Chaîne d'amplification en mode de courant, amplificateur opérationnel, cellule de gain et élément d'amplification correspondants. |
| JPH08188546A (ja) * | 1995-01-04 | 1996-07-23 | Kyowa Hakko Kogyo Co Ltd | カルコン誘導体 |
| GB9519490D0 (en) | 1995-09-25 | 1995-11-29 | Melvin William T | Use of a cytochrome P450 enzyme in tumour cells as a marker and target |
| US5966032A (en) | 1996-09-27 | 1999-10-12 | Northern Telecom Limited | BiCMOS transceiver (driver and receiver) for gigahertz operation |
| GB9802522D0 (en) | 1998-02-06 | 1998-04-01 | Montford University De | Hydroxylation activated prodrugs |
| JP4642226B2 (ja) | 1998-02-06 | 2011-03-02 | デ モントフォート ユニヴァーシティ | ヒドロキシル化により活性化されたプロドラッグ |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
| WO1999040944A2 (en) | 1998-02-12 | 1999-08-19 | De Montfort University | Hydroxylation activated drug release |
-
1999
- 1999-02-02 JP JP2000530488A patent/JP4642226B2/ja not_active Expired - Fee Related
- 1999-02-02 ES ES99901732T patent/ES2226332T3/es not_active Expired - Lifetime
- 1999-02-02 AU AU21738/99A patent/AU2173899A/en not_active Abandoned
- 1999-02-02 EP EP99901732A patent/EP1051383B1/en not_active Expired - Lifetime
- 1999-02-02 DE DE69918950T patent/DE69918950T2/de not_active Expired - Lifetime
- 1999-02-02 AT AT99901732T patent/ATE272040T1/de active
- 1999-02-02 WO PCT/GB1999/000155 patent/WO1999040056A1/en not_active Ceased
- 1999-02-02 CA CA2319836A patent/CA2319836C/en not_active Expired - Fee Related
-
2000
- 2000-08-07 US US09/633,699 patent/US6677383B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/765,861 patent/US6346550B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002502836A5 (https=) | ||
| JP2002510633A5 (https=) | ||
| JP2003531118A5 (https=) | ||
| CA2319836A1 (en) | Hydroxylation activated prodrugs | |
| JP2004505004A5 (https=) | ||
| AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| MY127946A (en) | Therapeutic formulation for administering tolterodine with controlled release | |
| JP2003521471A5 (https=) | ||
| JP2002508347A5 (https=) | ||
| JP2002518502A5 (https=) | ||
| JP2002541199A5 (https=) | ||
| JP2002513793A5 (https=) | ||
| RU2003100076A (ru) | Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х | |
| BR0115910A (pt) | Compostos orgânicos | |
| JP2003533479A5 (https=) | ||
| JP2001520998A5 (https=) | ||
| JP2002509153A5 (https=) | ||
| MXPA03008223A (es) | Compuesto para tratamiento de enfermedades inflamatorias. | |
| JP2008518890A5 (https=) | ||
| AU2001288899A1 (en) | Inhibitors of nadh:ubiquinone oxidoreductase | |
| WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
| CA2577740A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| JP2006510658A5 (https=) | ||
| JP2002520286A5 (https=) | ||
| JP2003529542A5 (https=) |